SG11201509680TA - Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. - Google Patents

Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Info

Publication number
SG11201509680TA
SG11201509680TA SG11201509680TA SG11201509680TA SG11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA
Authority
SG
Singapore
Prior art keywords
9alpha
oxoandrosta
6alpha
16alpha
methylbutyryloxy
Prior art date
Application number
SG11201509680TA
Inventor
Jiten Ranchhodbhai Patel
Gopalkumar Chimanlal Patel
Gaurav Sanjivkumar Sheth
Sanjay Nandlal Mandhane
Chitturi Trinadha Rao
Rajamannar Thennati
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of SG11201509680TA publication Critical patent/SG11201509680TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
SG11201509680TA 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. SG11201509680TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (1)

Publication Number Publication Date
SG11201509680TA true SG11201509680TA (en) 2015-12-30

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509680TA SG11201509680TA (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Country Status (18)

Country Link
US (1) US9458187B2 (en)
EP (1) EP3004133B1 (en)
JP (1) JP6366696B2 (en)
KR (1) KR20160030085A (en)
CN (1) CN105431445A (en)
AU (1) AU2014272640B2 (en)
BR (1) BR112015029530A8 (en)
CA (1) CA2912400A1 (en)
EA (1) EA027831B9 (en)
ES (1) ES2664019T3 (en)
IL (1) IL242658A0 (en)
MX (1) MX2015016283A (en)
MY (1) MY179214A (en)
PH (1) PH12015502652A1 (en)
SG (1) SG11201509680TA (en)
UA (1) UA117248C2 (en)
WO (1) WO2014192027A1 (en)
ZA (1) ZA201508640B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431445A (en) 2013-05-28 2016-03-23 太阳医药高级研究有限公司 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
SG11201706104XA (en) * 2015-01-31 2017-08-30 Sun Pharma Advanced Res Co Ltd CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6a,9a-DIFLUORO-17a,-(FURAN-2-YL)CARBONYLOXY-11ß-HYDROXY-16a-METHY1-3-OXOANDROSTA-1,4-DIENE-17ß-CARBOTHIOATE
CN106279341A (en) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 A kind of preparation method of fluticasone furoate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
US7208613B2 (en) 2002-06-20 2007-04-24 Sun Pharmaceutical Industries Limited Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (en) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11B-HYDROXIANDROSTA-4-ENO-3-ONAS
CN105431445A (en) 2013-05-28 2016-03-23 太阳医药高级研究有限公司 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Also Published As

Publication number Publication date
BR112015029530A8 (en) 2019-12-17
JP2016520122A (en) 2016-07-11
EA201592283A1 (en) 2016-04-29
EA027831B9 (en) 2017-12-29
AU2014272640B2 (en) 2018-04-05
US20160102117A1 (en) 2016-04-14
KR20160030085A (en) 2016-03-16
IL242658A0 (en) 2016-02-01
WO2014192027A1 (en) 2014-12-04
PH12015502652A1 (en) 2016-03-07
AU2014272640A1 (en) 2015-11-26
UA117248C2 (en) 2018-07-10
JP6366696B2 (en) 2018-08-01
EP3004133A1 (en) 2016-04-13
ES2664019T3 (en) 2018-04-18
MY179214A (en) 2020-11-02
EA027831B1 (en) 2017-09-29
MX2015016283A (en) 2016-03-11
BR112015029530A2 (en) 2017-07-25
CN105431445A (en) 2016-03-23
CA2912400A1 (en) 2014-12-04
EP3004133B1 (en) 2018-03-07
ZA201508640B (en) 2017-09-27
US9458187B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
IL243976B (en) Kdm1a inhibitors for the treatment of disease
HK1215378A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP3027192A4 (en) Methods for the treatment of solid tumors
PL3030663T3 (en) Compositions and methods for controlling leptinotarsa
EP3019491A4 (en) Kinase inhibitors for the treatment of disease
DK2988743T3 (en) HETEROCYCLIC COMPOUNDS WHICH MAY BE USED FOR DISEASE TREATMENT
SG11201600918PA (en) Method for authenticating transactions
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
HK1220324A1 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP2945639A4 (en) Methods for treating cardiac conditions
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
EP2945643A4 (en) Therapeutic agents, compositions, and methods for glycemic control
EP3307068A4 (en) Mct4 inhibitors for treating disease
EP3316887A4 (en) Gls1 inhibitors for treating disease
SG11201507352YA (en) Methods for purifying 5-(halomethyl)furfural
PL3046914T3 (en) Methods for producing 5-(halomethyl) furfural
AP2015008803A0 (en) Methods for treating psoriasis using an anti-il-23antibody
FI20135921A (en) Method for treating metals
AU2014306716B2 (en) Compositions and methods for treating celiac sprue disease
EP3362205A4 (en) Methods for improving the thermal treatment of castings
EP3082841A4 (en) Methods for treating an animal
ZA201508640B (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate
EP3054022A4 (en) Method for thermally treating ring-shaped member
WO2014140856A3 (en) Mir-142 and antagonists thereof for treating disease
PL2964607T3 (en) Process for the preparation of halogen-n, n-dimethylbenzylamines